The Navigator Company (NVG) Q3 2024 earnings summary

Executive summary

• Turnover reached €1,569 million for the first nine months of 2024, up 7% year-on-year, with EBITDA at €431 million (+15%) and net profit at €241 million (+20%), driven by resilient prices, tissue and packaging growth, and cost management.

• Diversification into tissue and packaging segments contributed significantly, with tissue sales up 53% and packaging sales volume up 108% year-on-year, supported by the launch of integrated molded fiber packaging and the acquisition of Navigator Tissue UK.

• Integration of Accrol and Navigator Tissue UK progressed smoothly, supporting growth in tissue and packaging.

• Cash cost reductions of 4–12% year-on-year across all segments supported margins and profitability.

• Net debt increased mainly due to the Accrol acquisition, capex, and dividend distribution, with Net Debt/EBITDA at 1.16x.

Financial highlights

• EBITDA margin improved to 27.5% (+1.7 pp year-on-year); Q3 EBITDA was €133 million (26.3% margin).

• Free cash flow for 9M was negative (€-3 million), mainly due to capex, M&A, and dividend outflows.

• Capex totaled €151 million, with 53% allocated to ESG and sustainability projects.

• Net debt increased by €150–153 million, mainly due to Accrol acquisition and €150 million in dividends.

• Average financing cost at 2.3%, with 93% of debt at fixed rates.

Outlook and guidance

• Q4 started with macroeconomic and geopolitical uncertainty, but sector forecasts remain cautiously optimistic.

• Pulp prices expected to recover in China, with positive price pressure from Latin American capacity cuts and maintenance shutdowns.

• Paper and packaging entering a strong seasonal period, with order inflow rising and European mill closures expected to support prices.

• Tissue demand in Europe projected to grow 5–6% in 2024, with synergies from recent acquisitions.

• Continued focus on operational efficiency, cost management, and business diversification, especially in tissue and packaging.